Mobile Site ›

Von Willebrand Disease (VWD)
Part 2: NHLBI Diagnosis Guidelines

Laboratory Recommendations



Introduction

Slide 1

May 2011


Welcome to Mayo Medical Laboratories' Hot Topics. These presentations provide short discussions of current topics and may be helpful to you in your practice.

Our presenter for this program is William L. Nichols, MD, consultant in the Special Coagulation Laboratory and Hemophilia Center at Mayo Clinic in Rochester, Minnesota. In Part 2 of this 2- part presentation, Dr. Nichols will provide a brief review of the clinical recommendations in diagnosing von Willebrand disease (VWD) from Part 1 and explain recommendations for laboratory assessment for VWD, primarily based on guidelines from the National Heart, Lung, and Blood Institute expert panel.

Thank you for tuning in for Mayo Medical Laboratories’ Hot Topics series on von Willebrand disease (VWD). For this second of 2 short presentations on VWD Diagnosis Guidelines, I will focus on reviewing recommendations for the laboratory evaluation for VWD. The first presentation (part 1) introduced von Willebrand factor (VWF) and its biology, and provided information about clinical aspects of hereditary VWD as well as acquired von Willebrand syndrome (AVWS), with a discussion of recommendations for clinical assessment for VWD. My discussion will be mainly based on the evidence-based guidelines from the National Heart, Lung, and Blood Institute (NHLBI) expert panel report in 2008.

Introduction

 

Jump to section:


Key